Clascoterone for Hair Regrowth

Evidence Review created on 08/08/2026 using AI4L / Opus 5

Also known as: Cortexolone 17α-propionate, CB-03-01, Breezula, Winlevi

Motivation

Clascoterone is a hormone-blocking medication applied directly to the skin. It was first approved as a cream for acne, where it works by stopping male-type hormones from acting on the oil glands of the face. Because those same hormones drive the slow thinning of scalp hair known as pattern baldness, a stronger scalp version of the identical molecule has been developed specifically for hair loss.

Pattern hair loss affects roughly four in ten men worldwide and a large share of women as they age. The two long-standing medicines for it either act on the whole body or work on blood flow to the follicle rather than on the hormonal cause. A scalp-applied hormone blocker is appealing because it aims at that cause while breaking down into an inactive form as soon as it enters the bloodstream. Large late-stage trials in men finished recently, and no regulator has yet reviewed them.

This review examines what is known about clascoterone applied to the scalp: how it works, what the effectiveness and safety record shows, how much of that record is publicly available in full, how the compound is used in practice, and where the open questions lie.

Benefits - Risks - Protocol - Conclusion

Recommended Reading

A short, curated set of high-level resources that frame clascoterone within the wider landscape of androgen-driven hair loss and document its proposed mechanism.

• #316 – AMA #63: A guide for hair loss: causes, treatments, transplants, and sex-specific considerations - Peter Attia

  A structured walk through androgenetic alopecia (the medical term for pattern hair loss) that treats dihydrotestosterone (the potent testosterone derivative that shrinks scalp follicles) as the central lever, and works through the trade-offs of every currently available option. This item qualifies through the shared target rather than by naming clascoterone: it is the same androgen signal at the follicle that clascoterone blocks, and it is the best single map of what an androgen-directed treatment has to beat.

• The Science of Healthy Hair, Hair Loss and How to Regrow Hair - Andrew Huberman

  A mechanistic overview of hair-follicle biology, the follicle stem-cell niche, and why androgen-driven miniaturization behaves differently from blood-flow-driven thinning. It qualifies via the shared mechanism — signalling through the androgen receptor (the docking protein inside the cell through which male-type hormones switch genes on and off) in scalp follicles, the exact target clascoterone occupies — and is useful for understanding why an androgen blocker and a vasodilator (a drug class that widens blood vessels to increase local blood flow) such as minoxidil are complementary rather than interchangeable.

• Hair Loss - Maureen Williams & Shayna Sandhaus

  A protocol-style review of pattern hair loss covering the diagnostic workup, the conventional drug options and their limitations, and the nutritional and integrative measures that modify outcomes. It qualifies via the shared target rather than by naming clascoterone — it works through dihydrotestosterone acting at the androgen receptor in scalp dermal papilla cells (the signalling hub at the base of each hair follicle), the exact signal clascoterone intercepts — and its particular value here is the baseline-status workup, iron stores, thyroid and vitamin D, that determines whether any androgen-directed treatment can work at all.

• Cortexolone 17α-Propionate (Clascoterone) is an Androgen Receptor Antagonist in Dermal Papilla Cells In Vitro - Rosette et al., 2019

  The foundational laboratory paper for the hair-loss indication: it shows clascoterone blocking androgen-driven gene activity with potency comparable to finasteride, and suppressing dihydrotestosterone-induced interleukin-6 (an inflammatory signalling protein) release from scalp dermal papilla cells. Note the conflict of interest that runs through essentially the entire clascoterone evidence base and is flagged again below: all five authors were employees of or affiliated with Cassiopea, the developer of the compound, now part of Cosmo Pharmaceuticals.

• Aliquot #112: Approaches to Reverse Hair Loss and Graying - Rhonda Patrick

  A topic-focused episode working through the evidence for reversing hair loss, from dietary and topical attempts to lower dihydrotestosterone to low-level laser therapy and the follicle changes that accompany aging. It qualifies via the shared target rather than by naming clascoterone: dihydrotestosterone acting at the androgen receptor in scalp follicles is the same signal clascoterone intercepts, and this episode is the most direct assessment of how weak the non-prescription attempts at that target actually are.

Content from two of the six priority platforms could not be included: searches of chriskresser.com and lifespan.io returned no article, episode or commentary that discusses clascoterone, its androgen-receptor mechanism, or androgenetic alopecia in substantial depth, so nothing from those platforms met the relevance bar.

Grokipedia

Clascoterone

The article covers clascoterone’s chemistry, its androgen-receptor mechanism, the acne approval pathway, and its investigational use in androgenetic alopecia, with the regulatory documentation cited inline. It is a useful orientation to the compound’s identity across its two indications before the trial evidence is examined in detail.

Examine

No Examine article exists for clascoterone.

Clascoterone is a prescription pharmaceutical, not a dietary supplement or food-derived compound. Examine.com’s coverage is confined to supplements, nutrients and dietary interventions and does not typically extend to prescription medications, so the absence of an entry is expected rather than a gap in the site’s coverage.

ConsumerLab

No ConsumerLab article exists for clascoterone.

ConsumerLab performs independent purity and potency testing on dietary supplements and consumer health products. It does not typically cover prescription medications, whose identity and potency are governed by regulatory manufacturing standards rather than by third-party market surveillance, so no entry for clascoterone would be expected.

Systematic Reviews

Pooled analyses of clascoterone’s randomized evidence; note that every one of them concerns the approved facial-acne indication, because no systematic review or meta-analysis of clascoterone in hair loss has yet been published.

• Efficacy and safety of topical clascoterone cream for treatment of acne vulgaris: A systematic review and meta-analysis of randomized placebo-controlled trials - Alkhodaidi et al., 2021

  The most direct pooled estimate of clascoterone’s effect and safety, covering five trials and 2,457 patients with an overall low risk of bias. Its safety analysis is the single most useful transferable finding for a hair-loss reader: across the adverse-event categories examined, clascoterone was essentially indistinguishable from vehicle (the inactive carrier solution used as the placebo comparator in these trials).

• Comparison of the Efficacy of Clascoterone, Trifarotene, and Tazarotene for the Treatment of Acne: A Systematic Literature Review and Meta-Analysis - Shergill et al., 2024

  A six-trial comparison placing clascoterone against two newer topical retinoids (vitamin A-derived creams that speed up skin cell turnover) on identical endpoints, finding no significant efficacy separation between them at twelve weeks. It is valuable as a calibration exercise: it shows clascoterone performing at the level of established topical agents rather than beyond them.

• The efficacy of Topical Clascoterone versus systematic spironolactone for treatment of acne vulgaris: A systematic review and network meta-analysis - Basendwh et al., 2024

  A network meta-analysis of seven studies and 2,006 patients that indirectly compares a topical androgen blocker with an oral one. The topical-versus-oral antiandrogen comparison is the central strategic question for anyone considering clascoterone for the scalp, and this is the only pooled analysis that attempts it.

• Topical, light-based, and complementary interventions for acne: an overview of systematic reviews - Yuan et al., 2024

  A Cochrane overview that screened 733 records and retained only six low-risk-of-bias reviews covering 40,910 patients, applying formal certainty grading throughout. Its explicit conclusion that pooled analysis of clascoterone is still an outstanding research need is the most rigorous available statement of how thin the independent synthesis of this compound remains.

• Efficacy of Topical Treatments in the Management of Mild-to-Moderate Acne Vulgaris: A Systematic Review - Althwanay et al., 2024

  A broader systematic review that positions clascoterone against topical antibiotics, retinoids, niacinamide and azelaic acid within a single evidence frame. It is useful for judging clascoterone’s relative standing among topical agents rather than only against an inert vehicle.

No systematic review or meta-analysis of clascoterone for androgenetic alopecia exists as of 08 August 2026. A structural point applies to all five papers above: the underlying randomized trials they pool were designed, funded and reported by Cassiopea and Sun Pharmaceutical Industries, the developer and the United States marketer of the compound, so the independence lies in the synthesis rather than in the primary data.

Mechanism of Action

Clascoterone is the 17α-propionate ester of cortexolone (11-deoxycortisol), a naturally occurring steroid intermediate. Adding the propionate group converts a hormonally quiet molecule into a high-affinity competitive antagonist at the androgen receptor (the intracellular docking protein through which testosterone and its more potent derivative dihydrotestosterone switch genes on and off).

• Competitive blockade at the follicle: In androgenetic alopecia, dihydrotestosterone binds the androgen receptor inside dermal papilla cells (the signalling hub sitting at the base of each hair follicle) and switches on a transcriptional programme that shortens the growth phase and progressively miniaturizes the follicle. Clascoterone occupies the same receptor without activating it, so the androgen signal is intercepted at its endpoint rather than upstream.

• Potency comparable to finasteride, by a different route: In androgen-receptor reporter cells, clascoterone inhibited testosterone-driven transcription with a half-maximal inhibitory concentration of 1.55 × 10⁻⁶ M against 2.89 × 10⁻⁶ M for finasteride — the same order of magnitude. The two drugs are not interchangeable mechanistically: finasteride inhibits 5-alpha reductase (the enzyme that converts testosterone into dihydrotestosterone) and therefore lowers hormone supply throughout the body, whereas clascoterone leaves hormone levels untouched and blocks the receiving end locally.

• An anti-inflammatory component: Dihydrotestosterone-stimulated scalp dermal papilla cells secrete interleukin-6, an inflammatory signalling protein implicated in follicular miniaturization. Clascoterone suppressed this secretion substantially more effectively than enzalutamide, another direct androgen-receptor antagonist, while neither agent affected basic fibroblast growth factor, a separate cell-growth signal. This suggests part of the effect may be inflammatory rather than purely hormonal.

• Continuous occupancy is required: In washout experiments, removing clascoterone after twelve hours and re-exposing the cells to dihydrotestosterone caused receptor blockade to collapse. Sustained antagonism required the drug to remain present — the direct laboratory rationale for twice-daily rather than once-daily application.

• Deliberate peripheral selectivity: Skin and plasma esterases (enzymes that split ester bonds) cleave the propionate ester rapidly, yielding cortexolone, which has negligible androgen-receptor activity. The drug is therefore active where it is applied and inactivated once it reaches the circulation. In the maximal-use pharmacokinetic study, cortexolone plasma concentrations stayed below the 0.5 ng/mL limit of quantitation.

Key Pharmacological Properties

• Half-life and dosing interval: Systemic exposure reaches steady state by day 5 of twice-daily use, with plasma concentrations roughly 1.8- to 2.1-fold above first-dose levels — an accumulation ratio consistent with a short plasma persistence relative to the twelve-hour dosing interval. No terminal elimination half-life for clascoterone has been reported in the published Phase 1 dataset, which is a genuine gap in the public pharmacology; the functional half-life that matters clinically is the receptor-occupancy window demonstrated in the washout work above, which is shorter than twenty-four hours.

• Selectivity: Clascoterone is a peripherally selective androgen-receptor antagonist. It shows no meaningful oestrogenic or progestogenic activity, and because it is inactivated on absorption it does not produce the systemic antiandrogen profile of spironolactone or bicalutamide.

• Tissue distribution: Distribution is essentially confined to the application site. Plasma protein binding is 84% to 89% and concentration-independent. Peak plasma concentration after two weeks of the 1% cream applied at roughly 6 g twice daily, about 12 g per day, across face and trunk was 4.5 ± 2.9 ng/mL, with an area under the curve over the dosing interval of 37.1 ± 22.3 h·ng/mL.

• Metabolism and elimination: The primary route is esterase-mediated hydrolysis in skin and plasma to cortexolone, then onward to tetrahydrocortexolone and glucuronide conjugates. Cytochrome P450 enzymes such as CYP3A4 (the liver enzyme family responsible for most drug-drug interactions) are not the principal pathway, which is the pharmacological basis for clascoterone’s very low interaction potential. Less than 1% of an applied dose is recovered in urine as conjugated esters.

Competing Mechanistic Interpretations

• Receptor blockade versus hormone reduction: The developer’s position is that intercepting the androgen signal at the receptor is sufficient and inherently safer than lowering dihydrotestosterone systemically. The counter-argument, advanced by proponents of 5-alpha reductase inhibition, is that a competitive antagonist must out-compete a continuously replenished ligand at every follicle, and that any lapse in application restores full androgen signalling — precisely what the washout experiments show. Both readings are consistent with the same laboratory data; the twelve-month withdrawal data described under Expected Benefits favour the second reading on durability while supporting the first on safety.

• The dihydrotestosterone paradox: Androgens miniaturize scalp follicles while enlarging beard and body follicles, so androgen receptor occupancy alone cannot explain the phenotype. Competing explanations invoke regional differences in receptor density inherited independently of hormone levels, local prostaglandin signalling (a lipid messenger system that regulates inflammation and hair-cycle timing), and follicular inflammation. Clascoterone’s interleukin-6 effect is consistent with the inflammatory account, but no clinical data currently discriminate between these explanations.

Historical Context & Evolution

• Origin as a topical antiandrogen, not a hair drug: Cortexolone 17α-propionate was first characterized pharmacologically by Celasco and colleagues in 2004 as a topical, peripherally selective androgen antagonist. The design intent from the outset was to obtain antiandrogen activity in skin without the systemic hormonal consequences that had limited oral agents, and the earliest development targets were androgen-driven skin conditions rather than hair.

• Acne first, because the endpoint was easier: The compound entered clinical development for acne vulgaris, where sebaceous glands are the androgen-responsive tissue, lesion counts give a fast and countable endpoint, and trials read out in twelve weeks rather than twelve months. Two Phase 3 randomized trials led to United States approval of the 1% cream as Winlevi in August 2020 — the first genuinely new mechanism approved for acne in roughly four decades.

• The hair programme ran in parallel, not afterwards: A Phase 2 proof-of-concept study in 95 men with androgenetic alopecia comparing a 5% solution against 5% minoxidil and vehicle over 26 weeks began in October 2014, well before the acne approval. Its detailed results were never published or posted, which is the first instance of a pattern that persists to the present.

• What the intermediate studies actually found: A subsequent twelve-month dose-ranging Phase 2 study in more than 400 men in Germany tested 2.5%, 5% and 7.5% solutions twice daily and 7.5% once daily against vehicle. All active groups showed statistically significant improvement over vehicle in target-area hair count (the number of visible non-vellus hairs, meaning the thicker pigmented hairs rather than fine downy ones, in a marked patch of scalp), with the 7.5% twice-daily arm performing best and also showing the largest gain in hair width. A separate Phase 2 study in 293 women aged 18 to 55 found a statistically significant hair-count improvement only in the 5% arm and only in the subgroup under 30. Both sets of findings reached the public solely through company press releases.

• How the reading of the evidence has shifted, and why: Between 2019 and 2025 the field’s view moved from “promising laboratory antiandrogen” to “the first plausible new mechanism for pattern hair loss in over thirty years”, driven by the Phase 3 readouts rather than by any new mechanistic insight. That shift should not be read as settled: the mechanistic case was already strong in 2019 and the clinical case still rests on data that no independent reviewer has seen in full. The evidence that could move the reading in the other direction — a peer-reviewed publication showing the absolute hair-count gains to be modest, or a regulatory review identifying inconsistencies between the two pivotal trials — has simply not been produced yet in either direction.

Expected Benefits

High 🟩 🟩 🟩

Reduction of Androgen-Driven Sebum Production and Acne Lesions

Clascoterone’s best-documented clinical effect is on the sebaceous gland, the other androgen-responsive structure of the hair follicle and its attached oil gland. Blocking the androgen receptor in the oil-producing cells of that gland reduces lipid output and inflammatory cytokine release, which translates into fewer lesions and less facial oiliness. The evidence basis is unusually solid for a dermatological agent: two identically designed Phase 3 randomized controlled trials (studies in which participants are randomly assigned to drug or vehicle) plus at least four independent meta-analyses. The relevance to a hair-loss reader is twofold: it demonstrates that the molecule engages its target in human skin at practical doses, and scalp seborrhoea (excess oil production by the scalp) frequently accompanies pattern hair loss. The limitation is that facial skin and scalp skin differ in thickness, follicle density and barrier properties, so target engagement in one does not quantify effect size in the other.

Magnitude: Pooled across five randomized trials and 2,457 patients, clascoterone roughly tripled the chance of treatment success on the investigator’s global rating (risk ratio 2.87, meaning success was 2.87 times as likely as with vehicle; 95% confidence interval 2.11–3.89, the range within which the true value most likely falls) and reduced non-inflammatory lesion counts by 5.64 lesions versus vehicle.

Local Androgen Blockade Without Systemic Hormonal Disruption

The central practical advantage of clascoterone over every established antiandrogen approach is that it does not measurably alter circulating hormones. The propionate ester is cleaved by esterases on absorption, so the compound that reaches the bloodstream is cortexolone, which does not meaningfully occupy the androgen receptor. This is established across five published Phase 1 studies plus a maximal-use pharmacokinetic study, and reinforced by twelve months of Phase 3 safety follow-up in men treating the scalp. For a reader who has declined or discontinued finasteride or dutasteride over concerns about libido, mood, semen parameters or prostate-specific antigen interpretation, this is the specific attribute that makes clascoterone a different proposition rather than a reformulation of the same trade-off.

Magnitude: Steady-state peak plasma concentration of 4.5 ± 2.9 ng/mL after roughly 6 g twice daily of the 1% cream; the inactive metabolite cortexolone remained below the 0.5 ng/mL detection limit; less than 1% of the applied dose was recovered in urine; no significant systemic hormonal adverse effects were reported in the 1,465 men randomized into the six-month Phase 3 phase, nor across twelve months in the responder subset carried into the extension.

Medium 🟩 🟩

Increased Scalp Hair Count in Men with Mild-to-Moderate Pattern Hair Loss

Two identically designed Phase 3 trials, SCALP 1 and SCALP 2, randomized 1,465 men with Norwood-Hamilton stage III-vertex to V hair loss (a standard photographic grading of pattern baldness severity) 2:1 to clascoterone 5% solution or vehicle, applied 1.5 mL twice daily to the vertex and temples for six months. Both met the objective co-primary endpoint of target-area hair count at six months; the patient-rated hair-coverage co-primary was significant in one trial, a positive trend in the other, and significant only in the combined analysis. Two features hold this below a High grade. First, the two trials produced markedly different effect magnitudes despite identical protocols, which points to differences in site technique, baseline severity distribution or vehicle response rather than to a stable underlying effect size. Second, and more consequentially, no result has been published in a peer-reviewed journal or posted to ClinicalTrials.gov; everything known comes from investor announcements by Cosmo Pharmaceuticals, which owns the compound.

Magnitude: 539% relative improvement in target-area hair count versus vehicle in one trial and 168% in the other, both statistically significant at p < 0.05; absolute hair counts per square centimetre have not been disclosed.

Continued Accrual of Hair with Uninterrupted Use Through Twelve Months

Responders from the six-month phase were re-randomized to continue clascoterone or switch to vehicle for a further six months. Those who continued kept gaining hair from month 3 through month 12, while those switched to vehicle lost a measurable portion of what they had gained. This is the most clinically informative part of the programme, because it separates a genuine treatment-dependent effect from regression to the mean (the tendency for unusually high or low starting measurements to drift back toward average on retesting) or photographic artefact, and it establishes that the benefit is maintenance-dependent in the same way as every other androgen-directed hair treatment. The same caveat applies: the finding is known only from a company announcement, and the extension enrolled only participants already identified as responders, which inflates the apparent effect relative to an unselected population.

Magnitude: 239% relative improvement in target-area hair count at month 12 in men who remained on clascoterone versus those switched to vehicle after month 6.

Improvement in Self-Rated Hair Coverage and Treatment Satisfaction

Objective hair counts and subjective satisfaction diverge often enough in hair-loss trials that regulators now require both. In the Phase 3 programme the patient-reported co-primary endpoint reached significance in one trial, showed a positive trend in the other, and was statistically significant in the combined analysis, aligning with the objective hair counts. Participants also rated the alcohol-based solution acceptable to use at month 12, which matters because adherence to a twice-daily topical over years is the practical rate-limiter for any scalp therapy. The trials enrolled only men with mild-to-moderate loss, so these ratings do not speak to satisfaction in advanced baldness where cosmetic thresholds are much harder to cross.

Magnitude: 24.5% relative improvement in treatment satisfaction at month 12 versus vehicle groups.

Low 🟩

Increased Hair Shaft Width and Partial Reversal of Follicle Miniaturization ⚠️ Conflicted

Hair count and hair width are separable outcomes: a treatment can wake dormant follicles without thickening existing ones, and only width gain indicates true reversal of miniaturization rather than recruitment. The twelve-month Phase 2 dose-ranging study in more than 400 men reported the largest hair-width gain in the 7.5% twice-daily arm. The evidence is conflicted in a specific way: the dose selected for Phase 3 was 5%, not the 7.5% that performed best on width in Phase 2, and the Phase 3 programme has not reported hair width at all. Either the width advantage did not survive further evaluation, or it was traded against tolerability or manufacturing considerations. Neither the underlying data nor the dose-selection rationale has been published, so the two readings cannot be separated.

Magnitude: Not quantified in available studies.

Hair Count Improvement in Younger Women with Female Pattern Hair Loss ⚠️ Conflicted

A Phase 2 study randomized 293 women aged 18 to 55 across four arms of roughly 70 participants each — clascoterone 5%, clascoterone 7.5%, 2% minoxidil and vehicle, all twice daily for six months. The result was internally inconsistent: a statistically significant hair-count improvement appeared only with the 5% solution and only in the subgroup under 30, while the higher 7.5% dose did not reach significance. An inverted dose-response of this kind is more consistent with a chance subgroup finding than with a real effect, and the developer’s own response was to pursue only the male indication. Female pattern hair loss also typically presents decades later than 30, so even if the signal were genuine it would apply to a minority of affected women.

Magnitude: Not quantified in available studies.

Speculative 🟨

Additive Effect in Combination with Topical Minoxidil

Minoxidil acts on follicular blood flow and potassium channels, clascoterone on the androgen receptor — non-overlapping mechanisms that would in principle combine. No controlled trial has tested the combination for hair loss; every Phase 2 and Phase 3 clascoterone study explicitly excluded participants who had used minoxidil within twelve weeks. The basis for this expectation is therefore mechanistic reasoning plus analogy to the established finasteride-plus-minoxidil combination, together with in-vitro work showing clascoterone remains chemically stable when layered with other topical dermatological agents. Whether the alcohol-based vehicles of the two products are compatible on the same scalp, and whether irritation compounds, is untested.

Benefit in Other Androgen-Driven Skin and Hair Conditions

Case reports and mechanistic argument have proposed clascoterone for hirsutism (excess coarse hair growth in a male pattern in women), hidradenitis suppurativa (a chronic inflammatory disease of skin folds), seborrhoeic dermatitis (a common scaly, itchy rash of oil-rich skin) and pilonidal sinus disease (a recurring infected tract at the base of the spine), and a randomized Phase 2 trial in pilonidal disease is currently recruiting. For hair-loss readers the relevance is indirect: these indications would broaden the tolerability database and might make compounded supply easier to obtain, but none of them provides evidence about scalp efficacy. The basis at present is mechanistic and anecdotal only.

Benefit-Modifying Factors

• Androgen receptor gene variation: Variation in the androgen receptor gene (a common inherited difference in the gene coding for the receptor) on the X chromosome is the single strongest genetic association with androgenetic alopecia, and it works partly by altering receptor density and sensitivity in scalp skin. A competitive antagonist has to displace dihydrotestosterone from those receptors, so higher receptor density plausibly demands more sustained occupancy. No clascoterone trial has stratified by this variant, so the direction is inferred rather than demonstrated.

• 5-alpha reductase type II activity: Individuals whose scalp follicles generate high local dihydrotestosterone concentrations present clascoterone with more competing ligand to displace. This is the mechanistic argument for combining a receptor antagonist with an enzyme inhibitor rather than choosing between them, though no trial has tested the combination and the Phase 3 programme excluded anyone who had used finasteride or dutasteride within six months.

• Baseline severity and duration of loss: Both Phase 3 trials restricted enrolment to Norwood-Hamilton stage III-vertex to V, that is mild-to-moderate loss with follicles that are miniaturized but not yet fibrosed. Once a follicle has been replaced by fibrous tissue, no androgen blocker can recover it. Benefit should be expected to fall as baseline severity rises, and no data exist for stage VI-VII.

• Baseline iron stores, thyroid status and vitamin D: Low ferritin (the protein that stores iron and reflects total iron reserves), thyroid dysfunction and vitamin D insufficiency each drive diffuse shedding through mechanisms entirely separate from androgens. Any of them left uncorrected caps the visible result from an androgen-directed treatment, which is why the trials excluded participants with clinically significant iron or protein deficiency and uncontrolled thyroid disease.

• Sex: The male Phase 3 programme was positive; the female Phase 2 study was not, apart from an inconsistent under-30 subgroup. Female pattern hair loss differs in pattern, in the relative contribution of androgens, and in the frequency of non-androgen contributors such as iron deficiency and post-menopausal hormonal change, so male efficacy data should not be extrapolated to women.

• Age: All male participants were 18 or older with no upper limit in Phase 3, whereas the earlier Phase 2 work capped enrolment at 50 to 55 years. In the female study the only positive signal was in the youngest subgroup. For readers at the older end of the health-optimization range, the relevant consideration is that follicles lost decades ago are not recoverable and that age-related follicle-density decline proceeds independently of androgen signalling, so absolute gains should be expected to be smaller than the trial averages.

• Pre-existing scalp disease: Seborrhoeic dermatitis, psoriasis, folliculitis (inflammation of the hair follicles, usually seen as small red or pus-filled bumps) and scarring alopecias were exclusion criteria in every trial. Active scalp inflammation both confounds hair counting and impairs the barrier through which the drug is delivered, so uncontrolled scalp disease is expected to reduce measurable benefit.

• Adherence and application technique: The washout data show that receptor blockade collapses when the drug is absent. Missed evening applications, washing the scalp shortly after applying, and inadequate coverage of the temples are all plausible routes to a reduced effect, and adherence to a twice-daily topical over years is historically poor.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Local Skin Reactions at the Application Site

The consistent and expected adverse effect of clascoterone is irritation where it is applied: redness, itching, scaling, dryness and, less often, stinging, burning or swelling. The mechanism is a combination of the drug’s direct effect on the hair follicle and its attached oil gland and the vehicle itself — the scalp formulation is an alcohol-based solution, which is inherently drying. The evidence basis is the pooled Phase 3 acne dataset, where these were the most frequently reported reactions but occurred at rates at or below the vehicle arm, and the Phase 3 hair-loss programme, where local skin reactions were reported as comparable to vehicle across twelve months. Severity is typically mild, reactions are reversible on reducing frequency or stopping, and the approved labelling directs discontinuation or reduced frequency if they occur. Those with pre-existing seborrhoeic dermatitis or eczema of the scalp are the group most likely to be affected.

Magnitude: Erythema (redness), pruritus (itching) and scaling/dryness each occurred in 7% to 12% of patients in the acne trials; oedema (swelling), stinging and burning occurred in more than 3% but at rates similar to vehicle.

Medium 🟥 🟥

Reversible Suppression of the Cortisol Stress Axis ⚠️ Conflicted

Clascoterone is structurally a corticosteroid derivative, and the approved labelling carries an explicit warning that suppression of the hypothalamic-pituitary-adrenal axis (the hormone circuit that governs cortisol output) may occur during or after treatment. In the maximal-use Phase 2a study, three of 42 participants showed a blunted cortisol response to stimulation at day 14, all of whom normalized within four weeks and none of whom had clinical signs of adrenal insufficiency (too little cortisol production, which causes fatigue, low blood pressure and poor tolerance of physical stress). The evidence is directly conflicted: the developer’s position, supported by the pharmacokinetic data and by twelve-month Phase 3 follow-up reporting no significant systemic hormonal effects, is that systemic exposure is negligible; against this, a 2026 disproportionality analysis (a statistical screen that flags side effects reported more often for one drug than for all others) of the United States post-marketing adverse-event database identified hypothalamic-pituitary-adrenal axis suppression as a statistically strong reporting signal. Spontaneous reports cannot establish causation and are prone to notoriety bias (the tendency for an effect to be reported more often once a warning has drawn attention to it) from the label warning itself, but they also capture real-world use patterns — larger surface areas, longer duration — that trials exclude. The scalp regimen compounds this uncertainty: 1.5 mL of a 5% solution twice daily delivers roughly 150 mg of clascoterone per day, against roughly 20 mg from the labelled facial regimen of the 1% cream (about 1 g twice daily) and roughly 120 mg in the maximal-use study, where about 6 g twice daily was spread across face and trunk; no peer-reviewed pharmacokinetic study of the 5% scalp solution has been published.

Magnitude: Abnormal cortisol response in 3 of 42 subjects (7%) at day 14 in the maximal-use study — 1 of 20 adults (5%) and 2 of 22 adolescents (9%) — with all values between 14.9 and 17.7 µg/dL and full normalization by four weeks.

Elevated Blood Potassium

Clascoterone’s parent steroid is a mineralocorticoid-pathway intermediate, and blocking mineralocorticoid signalling promotes potassium retention — the same mechanism that makes hyperkalaemia (potassium above the normal blood range, which at high levels can disturb heart rhythm) the principal concern with spironolactone. Elevated potassium readings were observed in the clascoterone clinical programme and are noted in the approved labelling. The absolute signal is small and barely separates from vehicle, and no clinically significant hyperkalaemia was attributed to the drug in the acne trials; a dedicated analysis concluded that clinically relevant hyperkalaemia risk with topical clascoterone is low. The relevant risk concentrates in people already predisposed: reduced kidney function, potassium-sparing diuretics (a drug class that increases urine output while conserving potassium), ACE inhibitors (angiotensin-converting enzyme inhibitors, a blood-pressure drug class), angiotensin receptor blockers (a second blood-pressure drug class that blocks the same hormone signal one step further along), or high-dose potassium supplementation.

Magnitude: Shifts from normal to elevated potassium occurred in 5% of clascoterone-treated subjects versus 4% of vehicle-treated subjects.

Low 🟥

Post-Marketing Signals for Abnormal Hair Growth and Skin Striae

Analysis of 1,085 clascoterone-associated adverse-event reports in the United States post-marketing database detected 45 statistically disproportionate signals at the individual-term level. Beyond the expected erythema and dry skin, the analysis flagged skin striae (stretch marks, a recognized consequence of corticosteroid effect on dermal collagen) and abnormal hair growth. The mechanistic plausibility differs between them: striae are consistent with the compound’s corticosteroid backbone, whereas abnormal hair growth in either direction is exactly what would be reported for an antiandrogen applied near hair-bearing skin, and is confounded by the reason for use. A third flagged domain sits less comfortably with the local-action premise: reproductive system and breast disorders also reached a positive signal at the organ-class level, echoing the approved labelling, which already lists polycystic ovaries and amenorrhoea (absence of menstrual periods) as reproductive adverse reactions identified in trials and long-term safety studies, and which is precisely the event class that systemic antiandrogens produce and that peripheral inactivation is meant to prevent, although the analysis does not report which individual terms drove it and the reporting population for an acne drug skews young and hormonally active. Over 70% of reported events occurred within the first month of therapy, and disproportionality analysis identifies reporting patterns rather than causation, with reporting rates for a heavily marketed new topical inflated relative to older agents.

Magnitude: Skin and subcutaneous tissue disorders showed a reporting odds ratio of 1.83 (a measure of how much more often an event is reported for this drug than for all other drugs, where 1.0 means no excess; 95% confidence interval 1.58–2.12); reproductive system and breast disorders 1.88 (1.25–2.83), among 1,085 total reports from Q3 2020 to Q4 2024.

Contact Sensitization and Allergic Reaction

Any topical applied twice daily to the same skin for years carries a risk of delayed hypersensitivity to either the active compound or a vehicle excipient, presenting as an itchy, spreading eczematous reaction that worsens rather than improves with continued use. Clascoterone was formally tested for this: a dedicated 250-participant sensitization study and a 36-participant irritation study found irritation and sensitization potential minimal, and the approved labelling lists no contraindications other than known hypersensitivity. The residual concern is that the 5% scalp solution uses a different, alcohol-based vehicle that has not been through equivalent published irritation and sensitization testing, and that occlusion under hair differs from open facial application.

Magnitude: No evidence of irritation or sensitization in dedicated Phase 1 studies enrolling 36 and 250 healthy participants respectively.

Speculative 🟨

Higher Daily Drug Load from the 5% Scalp Solution

The entire published systemic-safety case for clascoterone rests on the 1% cream. The scalp regimen delivers roughly a quarter more drug per day than the highest exposure ever formally studied with that cream — the maximal-use regimen of about 6 g twice daily across face and trunk — and around seven times more than the labelled facial regimen, to skin with far higher follicular density, which is the primary route of transfollicular absorption. The developer reports negligible systemic exposure across the Phase 3 programme, but no peer-reviewed pharmacokinetic study of the 5% solution exists, so the assumption that facial-cream exposure data transfer to the scalp regimen is currently an inference rather than a demonstrated fact.

Theoretical Risk of Feminizing Effects on a Male Fetus

Systemic antiandrogens are avoided in pregnancy because androgen blockade during gestation can impair male genital development. Clascoterone’s inactivation on absorption makes meaningful fetal exposure unlikely, and the approved labelling reports insufficient human data rather than a contraindication. No pregnancy exposure data exist for the scalp regimen, and transfer risk from scalp-to-skin contact has not been studied. Controlled animal data do exist and sit behind the labelling: injected clascoterone produced malformations in rats at every dose level tested and increased post-implantation loss and resorptions in rabbits, at systemic exposures many times the maximum recommended human dose. The basis for the concern is therefore those animal findings combined with class-mechanistic reasoning, with no human data in either direction.

Unknown Consequences of Multi-Year Androgen Receptor Blockade in Scalp Skin

Androgen signalling in skin contributes to barrier lipid production, wound healing and sebaceous gland maintenance. Pattern hair loss requires treatment measured in decades, whereas the longest human exposure to clascoterone on the scalp is twelve months and to the facial cream around one year in the open-label extension. Whether sustained local receptor blockade produces gradual sebaceous atrophy, altered scalp microbiome or barrier changes over five or ten years is unknown; no controlled data exist in either direction.

Risk-Modifying Factors

• Reduced kidney function: The kidney is the principal route of potassium excretion, so anyone with meaningfully reduced kidney function has less capacity to buffer the small mineralocorticoid effect. This is the single clearest amplifier of the hyperkalaemia signal and the reason a baseline blood chemistry panel is worth having before starting.

• Baseline potassium and cortisol status: A potassium already in the upper part of the reference range, or an existing diagnosis of adrenal insufficiency or recent systemic corticosteroid use, moves both the potassium and cortisol-axis risks from theoretical to monitorable. Neither risk is meaningful in someone whose baseline values sit comfortably mid-range.

• Pre-existing scalp barrier disease: Seborrhoeic dermatitis, psoriasis, eczema and folliculitis all increase drug penetration through a disrupted barrier while independently causing the redness and scaling that would otherwise be attributed to the drug. This group faces both a higher irritation burden and a higher systemic absorption risk.

• Genetic and enzymatic variation: Because clascoterone is inactivated by non-specific carboxylesterases (enzymes that split ester bonds) rather than by cytochrome P450 enzymes, the common pharmacogenetic variants that alter drug metabolism — CYP2C9, CYP2D6 and CYP3A5 (liver enzymes that clear many drugs) — have no clear relevance here. Rare carboxylesterase 1 variants that reduce ester hydrolysis are the theoretically relevant genotype, since slower hydrolysis would raise systemic exposure of the active form, but no clascoterone study has examined this.

• Sex: Women have not been studied on the 5% scalp regimen beyond a single six-month Phase 2 trial, and the theoretical concerns that do not apply to men — pregnancy exposure, effects on a male fetus, interaction with hormonal contraception or menopausal hormone therapy — are entirely unquantified, beyond the polycystic ovaries and amenorrhoea already listed in the approved labelling for the 1% cream. Women of childbearing potential therefore carry a risk profile that is not merely different but largely uncharacterized.

• Age: Older adults were not excluded from the Phase 3 programme, but reduced kidney function, thinner skin with a more permeable barrier, and polypharmacy involving ACE inhibitors, angiotensin receptor blockers, potassium-sparing diuretics or non-steroidal anti-inflammatory drugs all become more prevalent with age. For readers at the older end of the target range, the potassium and absorption considerations are materially more relevant than for a 30-year-old.

• Total treated surface area and concurrent use: Risk scales with dose, and dose scales with area. Someone using the 1% cream on face, chest and back for acne while also applying the 5% solution to the scalp is receiving substantially more drug than either regimen was tested at.

Key Interactions & Contraindications

Clascoterone’s interaction profile is unusually quiet because it is hydrolysed by esterases rather than metabolized by cytochrome P450 enzymes and reaches the circulation as an inactive metabolite. The interactions that matter are pharmacodynamic — additive effects on potassium, the cortisol axis or local skin tolerance — rather than pharmacokinetic.

• Potassium-raising prescription medications — caution, monitor: ACE inhibitors (lisinopril, ramipril, enalapril), angiotensin receptor blockers (losartan, valsartan, telmisartan), potassium-sparing diuretics (spironolactone, eplerenone, amiloride, triamterene) and direct renin inhibitors (aliskiren; a blood-pressure drug class that blocks the same hormone system at its first step) all raise serum potassium. Combined with clascoterone’s small mineralocorticoid effect, the clinical consequence is hyperkalaemia with, at severe levels, cardiac arrhythmia. Mitigation: check serum potassium at baseline and at 4 weeks, and again after any dose increase in the co-administered drug.

• Systemic corticosteroids — caution, monitor: Oral, injected or high-potency inhaled corticosteroids (prednisone, dexamethasone, triamcinolone injections, high-dose fluticasone) suppress the cortisol axis directly. The clinical consequence of adding a topical corticosteroid-derived compound is additive suppression, with fatigue, low blood pressure on standing and impaired stress response. Mitigation: the Phase 3 protocol permitted only stable-dose inhaled, intranasal or ocular corticosteroids and excluded systemic use within twelve weeks — a reasonable template outside trials.

• Over-the-counter medications — caution: Non-steroidal anti-inflammatory drugs (ibuprofen, naproxen, diclofenac) reduce renal potassium excretion, and regular use adds to the hyperkalaemia risk described above; occasional use does not. Over-the-counter topical minoxidil is not a pharmacokinetic interaction but an additive irritant one when both alcohol-based solutions are applied to the same scalp, with the consequence of compounded dryness, itching and flaking. Mitigation: separate applications by at least four hours or alternate morning and evening.

• Potassium supplements and potassium-based salt substitutes — caution, monitor: Potassium chloride supplements, potassium-containing salt substitutes and very high-dose coconut water intake add exogenous potassium load. Consequence: hyperkalaemia, particularly alongside any of the drug classes above. Mitigation: avoid routine potassium supplementation without a documented deficiency, and monitor if both are used.

• Antiandrogenic supplements — caution: Saw palmetto (Serenoa repens), pygeum (Prunus africana), stinging nettle root (Urtica dioica), reishi mushroom (Ganoderma lucidum) and pumpkin seed oil are all promoted for hair loss on the basis of weak 5-alpha reductase inhibition. Their effect is additive with clascoterone’s rather than antagonistic, and the consequence is more theoretical than demonstrated, but they also confound any attempt to attribute a result to the drug. Every clascoterone trial excluded them for exactly that reason. Mitigation: if the aim is to evaluate clascoterone, hold these for at least two weeks before starting and throughout.

• Licorice root (Glycyrrhiza glabra) — caution, monitor: Glycyrrhizin inhibits the enzyme that inactivates cortisol in the kidney, producing a mineralocorticoid effect that raises blood pressure and lowers potassium. The interaction with clascoterone is directionally opposing on potassium but both act on the same axis, and the combination makes any abnormal reading uninterpretable. Mitigation: avoid sustained high-dose licorice while establishing a baseline.

• Other hair-loss interventions — monitor: Oral or topical finasteride and dutasteride act upstream of clascoterone with no known pharmacokinetic interaction and a plausible additive benefit; the consequence to watch is that combining them removes any ability to attribute either benefit or side effect. Microneedling within 24 hours of application substantially increases drug penetration and therefore systemic exposure, which is a genuine safety consideration rather than a theoretical one. Platelet-rich plasma (concentrated platelets prepared from a person’s own blood) and low-level light therapy have no known interaction. Mitigation: do not apply clascoterone to freshly microneedled scalp; wait at least 24 hours.

• Topical scalp corticosteroids, calcineurin inhibitors and retinoids — caution: Clobetasol, betamethasone, tacrolimus and pimecrolimus (calcineurin inhibitors, non-steroid creams that damp down local immune activity) and topical tretinoin applied to the same area increase irritation and, for corticosteroids, add to cortisol-axis suppression. Mitigation: separate by application site or time, and limit concurrent potent corticosteroid use to short courses.

Populations Who Should Avoid This Intervention

• Pregnancy and breastfeeding: No adequate human data exist for either the cream or the scalp solution, and the theoretical concern regarding male fetal development has not been excluded.

• Women of childbearing potential not using effective contraception: The Phase 3 programme required contraception even in the female partners of male participants, which indicates the developer’s own risk assessment.

• Documented adrenal insufficiency or current systemic corticosteroid therapy: Any condition already compromising the cortisol axis — Addison’s disease, secondary adrenal insufficiency, corticosteroid courses within the preceding 12 weeks — removes the physiological reserve that makes the drug’s small suppressive effect inconsequential.

• Chronic kidney disease at stage 3b or worse (estimated glomerular filtration rate below 45 mL/min/1.73 m², a calculated measure of kidney filtering capacity), or any baseline serum potassium above 5.0 mEq/L: These thresholds mark the point at which a 1% absolute increase in hyperkalaemia risk stops being negligible.

• Active uncontrolled scalp disease: Seborrhoeic dermatitis, scalp psoriasis, folliculitis, fungal infection or scalp atrophy should be treated to control before starting, since all were formal exclusion criteria in every trial.

• Non-androgenetic hair loss: Alopecia areata (patchy loss caused by the immune system attacking the follicle), scarring alopecias including frontal fibrosing alopecia and lichen planopilaris (forms in which the follicle is destroyed and replaced by scar tissue), telogen effluvium (diffuse shedding triggered by a physiological shock such as illness, surgery or rapid weight loss), and trichotillomania (compulsive hair pulling) do not respond to androgen blockade, and using clascoterone delays correct diagnosis of conditions where early treatment determines outcome.

• Adolescents under 18 for the hair indication: The 1% acne cream is approved from age 12, but no hair-loss trial enrolled anyone under 18, and pediatric patients are explicitly noted as more susceptible to systemic effects at higher surface-area-to-weight ratios.

Risk Mitigation Strategies

• Confirm the diagnosis before starting: Androgen blockade addresses only androgenetic alopecia. A dermatologist or trichologist evaluation with trichoscopy (magnified examination of the scalp surface) distinguishes pattern loss from alopecia areata, scarring alopecia and telogen effluvium, and prevents the specific harm of losing months of treatable window in a scarring alopecia while applying an ineffective topical.

• Establish baseline laboratory values: Serum potassium, a comprehensive metabolic panel including creatinine and estimated glomerular filtration rate, and an 8 a.m. serum cortisol before the first application. This mitigates the two systemic risks — hyperkalaemia and cortisol-axis suppression — by identifying the small minority who start with no physiological reserve, and by making any later abnormal value interpretable rather than alarming.

• Correct deficiency states first: Ferritin, thyroid-stimulating hormone with free thyroxine, and 25-hydroxyvitamin D before starting, with iron repletion targeting ferritin above 70 ng/mL where low. This mitigates the risk of attributing a poor result to drug failure when the actual limiter was a correctable deficiency, and avoids months of unnecessary exposure.

• Start once daily for the first two weeks: Applying 1.5 mL in the evening only for 10 to 14 days before escalating to twice daily mitigates the dominant risk — local irritation — by allowing the scalp barrier to adapt to an alcohol-based vehicle, and it identifies vehicle intolerance before a full month’s supply has been committed.

• Apply to a dry scalp and allow full drying: Applying to towel-dry rather than wet hair, spreading directly onto scalp skin rather than hair shafts, and allowing 20 to 30 minutes before lying down or covering the head reduces both run-off onto the forehead — where it can provoke facial irritation — and unintended transfer to a partner or child.

• Cap total treated area and total daily dose: Keeping to 1.5 mL twice daily on the scalp and not simultaneously running the 1% cream over face, chest and back mitigates the systemic risks of cortisol-axis suppression and hyperkalaemia, both of which scale with total dose absorbed rather than with concentration.

• Recheck potassium at 4 weeks, and after any change in co-medication: A single serum potassium 4 weeks after reaching the full twice-daily regimen, repeated whenever an ACE inhibitor, angiotensin receptor blocker, potassium-sparing diuretic or regular non-steroidal anti-inflammatory drug is added, mitigates hyperkalaemia risk at the point where it is actually likely to appear.

• Do not apply to broken, freshly microneedled or inflamed scalp: Waiting at least 24 hours after microneedling and treating active scalp dermatitis before resuming mitigates the risk of a large unintended increase in absorption, which is the most plausible route to a clinically meaningful systemic effect.

• Set a defined stop-assessment point: Deciding in advance to reassess with standardized photography at 6 months and to stop if no change is visible mitigates the risk of indefinite exposure and expense for a non-responder, which for an unapproved compounded product is the most probable adverse outcome of all.

Therapeutic Protocol

No regulator has approved clascoterone for hair loss anywhere as of August 2026, so there is no labelled protocol. What follows is the regimen used in the Phase 3 programme, which is the only dose and schedule supported by controlled data, together with the ways practitioners are handling the compound off-label.

• Trial regimen — the reference standard: 1.5 mL of a 5% clascoterone solution applied with a dropper directly to the balding areas of the vertex and temples, twice daily, morning and evening, continuously. This is the regimen that produced the Phase 3 results and the twelve-month safety dataset; both pivotal trials used it without modification.

• Dose selection rationale and the unresolved question: The Phase 2 dose-ranging study in over 400 men tested 2.5%, 5% and 7.5% twice daily plus 7.5% once daily. All active arms beat vehicle, with 7.5% twice daily best on both hair count and hair width, yet 5% was carried into Phase 3. The rationale has not been published. Compounded product at concentrations above 5% therefore rests on six-month Phase 2 data with no long-term safety dataset behind it at all.

• Competing approach — systemic androgen reduction: Oral finasteride 1 mg daily, or dutasteride 0.5 mg daily off-label, lowers dihydrotestosterone throughout the body and has decades of controlled data and regulatory approval behind it. This approach is more established and cheaper; clascoterone’s claim against it is confined to the side-effect profile, not to superior efficacy, and no head-to-head trial exists. Neither should be treated as the default from which the other must be justified.

• Competing approach — non-hormonal and procedural: Topical or low-dose oral minoxidil, microneedling, low-level light therapy and platelet-rich plasma act on follicular blood flow, wound-healing signalling and stem-cell activation rather than on androgens. The integrative-dermatology position, associated with clinicians such as Alan Bauman of Bauman Medical in Boca Raton, is that these are layered rather than chosen between, with an androgen-directed agent as one component of a stack. That position carries a financial interest of its own, alongside the sponsor’s: a private hair-restoration clinic bills for every layer of the stack it endorses, so the incentive runs toward more components rather than fewer. The conventional dermatological position favours sequential single-agent trials with objective measurement between steps. Both are defensible; the layered approach obtains results faster but makes attribution impossible.

• Who has championed the compound: Development was led by Cassiopea, spun out of Cosmo Pharmaceuticals, with Alessandro Mazzetti as study director across both the acne and hair programmes. Maria Hordinsky of the University of Minnesota Department of Dermatology served as a Phase 3 clinical investigator and has been the most prominent academic voice presenting the SCALP results. Both are directly connected to the sponsor.

• Best time of day: Twice daily at roughly twelve-hour intervals, morning and evening, is what the trials used and what the receptor-occupancy data support. There is no circadian argument for a specific clock time; what matters is even spacing, because the washout experiments show antagonism collapsing once the drug is absent. Evening application should precede sleep by at least 30 minutes to allow drying and avoid pillow transfer.

• Half-life and dosing frequency: No terminal half-life has been published, but the functional receptor-occupancy window is under 24 hours, and the Phase 2 once-daily 7.5% arm underperformed the twice-daily arms. Twice-daily dosing is therefore not a convention but a mechanistically required feature of the protocol.

• Single versus split dosing: Split dosing is mandatory, not optional. The daily quantity is defined per application (1.5 mL each time), not as a daily total to be divided, and applying 3 mL once daily has never been tested.

• Genetic considerations for protocol choice: No pharmacogenetic testing informs clascoterone dosing. Because inactivation is by carboxylesterases rather than cytochrome P450 enzymes, the variants commonly invoked in personalized dosing — CYP2C9 and CYP2D6 (liver enzymes that clear many drugs), COMT (which breaks down dopamine and adrenaline), MTHFR (which processes folate) and APOE4 (a cholesterol-transport variant) — have no established bearing. Androgen receptor gene variation is the genotype with the strongest theoretical relevance to response, but no trial has stratified by it and no clinical test is validated for this purpose.

• Sex-based differences in the protocol: The entire Phase 3 dosing rationale derives from male participants. The single female study used 5% and 7.5% twice daily for six months and produced an inconsistent result, so no validated female protocol exists. Women considering the compound are extrapolating from male dosing without supporting data.

• Age-related considerations: No dose adjustment by age has been studied. For readers at the older end of the range, the practical modification is not dose but surveillance — baseline and follow-up potassium and kidney function — since age-related decline in renal reserve and higher rates of co-prescribed potassium-raising drugs shift where the risk sits.

• Baseline biomarkers that shape the protocol: Ferritin, thyroid-stimulating hormone and 25-hydroxyvitamin D should be corrected before the six-month assessment clock starts, since an uncorrected deficiency will blunt the visible result and can be misread as non-response.

• Pre-existing conditions that alter the protocol: Active seborrhoeic dermatitis should be brought under control with an antifungal shampoo before starting, both to protect the barrier and to remove a confounder for irritation. Reduced kidney function or concurrent potassium-raising medication converts the potassium check from optional to necessary.

Discontinuation & Cycling

• Lifelong or nothing: Androgenetic alopecia is a chronic, progressive, genetically driven condition. Clascoterone does not modify the underlying androgen sensitivity of the follicle; it occupies receptors for as long as it is present. The twelve-month Phase 3 extension is the direct evidence: men who continued gained hair through month 12, while those switched to vehicle after month 6 lost a measurable share of their gains. Treatment is open-ended by design.

• No withdrawal syndrome, but loss of gains: There is no pharmacological withdrawal effect — no rebound, no hormonal readjustment, nothing that requires medical management on stopping. What happens is simpler and more consequential: androgen signalling resumes at full strength, and the follicles that were rescued resume miniaturizing. Based on the extension data and on the analogous finasteride literature, gains are expected to be lost over roughly 6 to 12 months.

• Tapering is not required: Because the effect is competitive receptor occupancy with no receptor upregulation or hormonal feedback loop demonstrated, there is no pharmacological rationale for a taper. Stopping abruptly is not known to cause an acute shed beyond the normal reversion described above. Some clinicians taper to twice-weekly application before stopping in order to make the transition visually gradual rather than for any physiological reason.

• Cycling is not supported and is mechanistically counterproductive: No trial has tested intermittent or cyclical use, and the in-vitro washout data argue directly against it — removing clascoterone for twelve hours was sufficient for androgen-receptor blockade to collapse. Unlike drugs where tolerance or receptor downregulation motivates a drug holiday, there is no evidence of diminishing response to clascoterone over twelve months, so the usual rationale for cycling does not apply.

• Planned interruptions carry a measurable cost: Travel, supply gaps from compounding pharmacies, or a pause before a planned pregnancy in a partner will each cost some accrued benefit. The practical implication is that supply continuity should be arranged in advance, particularly for an unapproved compounded product where availability is not guaranteed.

Sourcing and Quality

• The approved product is the wrong strength for the scalp: Winlevi 1% cream, marketed in the United States by Sun Pharmaceutical Industries, is the only regulator-approved clascoterone product available. It is a 1% cream indicated for acne, at one-fifth the concentration used in the hair trials, in a cream base designed for facial skin rather than a hair-bearing scalp. Using it for hair loss is off-label, under-dosed relative to the trial regimen, and cosmetically impractical on a haired scalp.

• Breezula is not yet purchasable anywhere: The 5% scalp solution has completed Phase 3 but has not been submitted to any regulator. Cosmo Pharmaceuticals has stated a United States New Drug Application is planned for early 2027, with a European Marketing Authorisation Application in parallel. Any product currently advertised as “Breezula” from an online vendor is not the trial formulation.

• Compounding pharmacies are the only realistic route, with real caveats: Some compounding pharmacies and telehealth prescribers prepare topical clascoterone solutions at 2.5% to 5%. What to look for: a pharmacy licensed in the relevant jurisdiction with a documented compounding accreditation, a certificate of analysis for the raw active ingredient identifying supplier and assay purity, a stated vehicle composition, an assigned beyond-use date, and a named prescriber taking clinical responsibility. Compounded preparations are not evaluated by any regulator for potency, stability or sterility.

• Research-chemical suppliers are a distinct and higher risk: Clascoterone powder sold for “research use only” carries no pharmaceutical quality assurance. Identity, purity and the presence of residual solvents or synthesis by-products are unverified, and self-formulation in ethanol or propylene glycol produces a solution of unknown concentration and stability. This is a materially different risk category from a licensed compounder.

• Formulation matters as much as concentration: The trial vehicle is a proprietary alcohol-based solution optimized for scalp delivery and dropper application, and Cosmo treats it as part of its intellectual property, with patents running to 2036. A compounded 5% solution matches the labelled concentration but not necessarily the delivery, so equivalent skin penetration should not be assumed. Encouragingly, in-vitro work shows clascoterone chemically stable when layered with a range of other topical agents, with 98% to 119% recovery, so degradation in a reasonable vehicle is not the primary concern — delivery is.

Practical Considerations

• Time to effect: Objective hair-count changes were measurable at 3 months in the Phase 3 trials, with the co-primary endpoints assessed at 6 months and continued accrual through 12 months in those who stayed on treatment. Cosmetically visible change generally lags measurable change; a 6-month assessment with standardized photography is the earliest reasonable decision point, and 12 months is the fairer one.

• Common pitfall — judging too early: The hair cycle imposes a floor on how fast any treatment can work, and an initial period of shedding as follicles synchronize is common with androgen-directed therapies. Stopping at 8 to 12 weeks because nothing has changed is the most frequent way an effective treatment is abandoned.

• Common pitfall — applying to hair instead of scalp: The drug has to reach follicular skin. Dropper application parted through the hair onto the scalp surface, section by section, delivers what spraying onto hair does not. This is the single most common technique error with any scalp solution.

• Common pitfall — treating the wrong diagnosis: Roughly a quarter of people who self-diagnose pattern hair loss have a contributing or alternative cause, most commonly telogen effluvium, iron deficiency or thyroid disease. Androgen blockade will not address any of them.

• Common pitfall — stacking everything at once: Starting clascoterone, minoxidil, microneedling and a supplement stack in the same month makes it impossible to know what worked or what caused an adverse effect, and it maximizes irritation.

• Regulatory status: Clascoterone is a prescription medicine. The 1% cream is approved in the United States, the European Union, Canada, Brazil and other markets for acne only. The 5% scalp solution is investigational everywhere. Any current hair-loss use is off-label or compounded, which also means no manufacturer liability, no pharmacovigilance pathway specific to the indication, and no insurance coverage.

• Cost and access, and the payer incentive behind it: The approved 1% cream runs roughly USD 500 to 850 for a 60 g tube without insurance in the United States, against a few dollars a month for generic finasteride and over-the-counter minoxidil. That gap is not incidental. Insurers and national health systems have a direct and systematic financial incentive to favour the generic options, which shapes formulary placement, prior-authorization friction and which comparative studies attract funding. The mirror-image incentive also deserves naming: the sponsor has no commercial reason to run a head-to-head trial against cheap generic finasteride, which is precisely the comparison a reader most needs and the one that does not exist. Anyone pursuing clascoterone for hair loss before approval should expect to pay entirely out of pocket, plausibly USD 100 to 300 per month from a compounding pharmacy, indefinitely.

Interaction with Foundational Habits

• Sleep: Direct interaction is minimal and no sleep-related adverse events emerged in any trial; the mechanism for a null result is straightforward, since the compound is inactivated before it reaches the brain. Two indirect considerations apply. The theoretical cortisol-axis effect, if it occurred, would blunt the normal morning cortisol rise that supports waking alertness, which is one reason morning cortisol is worth measuring rather than assumed. Practically, the alcohol-based evening application needs 20 to 30 minutes to dry before lying down, so it belongs at the start of an evening routine rather than at the end.

• Nutrition: No direct interaction with food, timing or macronutrient composition; the drug is topical and absorption is not meal-dependent. The important indirect interaction is potentiating in the wrong direction: potassium-rich eating patterns taken to an extreme — large daily volumes of coconut water, potassium-based salt substitutes, potassium supplements — add to the small potassium-retaining effect, which matters only if kidney function is reduced or a potassium-raising drug is co-prescribed. In the other direction, protein restriction, severe caloric deficit and low iron intake each independently cause hair shedding and will mask any benefit; every Phase 3 trial excluded participants with recent severe dietary change, bariatric surgery or documented iron or protein deficiency for exactly this reason.

• Exercise: No blunting of training adaptation is expected and none was reported. The mechanism matters here: because clascoterone does not lower circulating testosterone or dihydrotestosterone — unlike finasteride and dutasteride, where a systemic hormonal effect is unavoidable — there is no pathway by which it could impair muscle protein synthesis or strength adaptation. This is arguably the most relevant distinction for a training-focused reader. The practical interactions are mechanical rather than physiological: heavy sweating within an hour of application will wash the solution off before it is absorbed, so applying after training rather than before is sensible, and swimming pool chlorine on a freshly treated scalp adds to irritation. Anabolic steroid use, by contrast, is a genuine confounder — it accelerates androgenetic alopecia and was an explicit trial exclusion.

• Stress management: The interaction is indirect and runs through the cortisol axis in both directions. Chronic psychological stress raises cortisol and can precipitate telogen effluvium, which will be misread as treatment failure. From the other side, the labelled warning about hypothalamic-pituitary-adrenal axis suppression means that anyone with a heavy stress load and a borderline morning cortisol has less reserve for an additional suppressive input, which is the practical argument for measuring rather than assuming. There is no evidence that clascoterone alters subjective stress, mood or anxiety — a meaningful contrast with the mood effects reported by a minority of finasteride users, which are attributed to neurosteroids (hormone derivatives made in or acting on the brain), since clascoterone does not reduce the 5-alpha reduced steroids implicated in those reports.

Monitoring Protocol & Defining Success

Baseline testing should be completed before the first application, for two reasons: it identifies the small group in whom the potassium and cortisol-axis risks are real rather than theoretical, and it establishes reference values that make any later abnormal result interpretable. It also captures the correctable non-androgen contributors — iron, thyroid, vitamin D — that otherwise cap the achievable result and get misattributed to drug failure.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Serum potassium	4.0–4.5 mEq/L	Detects the mineralocorticoid-mediated potassium rise seen in clinical trials	Conventional reference range is 3.5–5.2 mEq/L, wider than the functional target. Avoid fist-clenching and prolonged tourniquet, and ensure prompt processing — both falsely elevate the result. Recheck 4 weeks after reaching full dose
Morning serum cortisol	12–18 µg/dL	Screens the hypothalamic-pituitary-adrenal (HPA) axis for the suppression noted in the approved labelling	The HPA axis is the hormone circuit governing cortisol output. Conventional range 6–23 µg/dL. Draw between 7 and 9 a.m. after a normal night’s sleep. A value below 10 µg/dL warrants a cosyntropin stimulation test, where synthetic adrenocorticotropic hormone (ACTH) is given and cortisol remeasured at 30 minutes
Ferritin	70–100 ng/mL	Iron storage protein; low reserves cause diffuse shedding and cap the response to any hair treatment	Conventional lower limit of ~15–30 ng/mL sits far below the level hair specialists target. Ferritin rises with inflammation, so pair with high-sensitivity C-reactive protein (hs-CRP — a general marker of inflammation in the body) to avoid a falsely reassuring value
Thyroid-stimulating hormone (TSH)	0.5–2.0 mIU/L	Thyroid dysfunction produces diffuse hair loss that mimics or compounds pattern loss	Conventional range extends to 4.5 mIU/L. Pair with free thyroxine (free T4) and free triiodothyronine (free T3); draw fasting in the morning, as TSH follows a daily rhythm
25-hydroxyvitamin D	40–60 ng/mL	The vitamin D receptor is required for normal hair-follicle cycling	Conventional sufficiency threshold is 30 ng/mL. No fasting required; interpret against season and latitude
Comprehensive metabolic panel (CMP)	Within conventional limits, with estimated glomerular filtration rate (eGFR) above 60 mL/min/1.73 m²	Kidney function determines how much capacity exists to excrete a potassium load	A CMP is a standard blood chemistry set covering kidney, liver and electrolytes; eGFR is a calculated measure of kidney filtering capacity. Fasting preferred for the glucose component. Repeat whenever a potassium-raising medication is started
Total testosterone	500–900 ng/dL (men)	Establishes a systemic hormonal reference point and confirms that topical use has not altered circulating androgens	Conventional range is roughly 300–1,000 ng/dL. Draw fasting before 10 a.m.; pair with sex hormone-binding globulin (SHBG — the carrier protein determining how much testosterone is free) if the total value is equivocal

Ongoing monitoring follows a defined cadence: serum potassium and a symptom review at 4 weeks after reaching the full twice-daily regimen; standardized photography and a scalp examination at 3 months; potassium, morning cortisol and photography at 6 months, which is the primary efficacy decision point; and thereafter potassium and photography every 6 to 12 months for as long as treatment continues, with an additional potassium check within 4 weeks of starting any ACE inhibitor, angiotensin receptor blocker, potassium-sparing diuretic or regular non-steroidal anti-inflammatory drug.

Objective hair measurement deserves its own discipline, because visual impressions over months are unreliable. Standardized global photography under fixed lighting, distance, hair length and part position at baseline, 3, 6 and 12 months is the minimum. Where available, phototrichogram or macrophotographic hair counts in a marked one-square-centimetre target area — the target-area hair count method used as the Phase 3 primary endpoint — provide the only quantitative measure that can distinguish a real change from a styling change.

Qualitative markers to track alongside the numbers:

• Daily shedding volume — hairs collected from pillow, shower drain and comb, ideally counted on a fixed weekday rather than estimated
• Scalp comfort — itching, burning, flaking or tightness, which flag the dominant adverse effect early enough to reduce frequency rather than stop
• Hair texture and styling behaviour — whether hair holds volume, feels thicker between the fingers, or requires less styling to achieve coverage
• Density at the part line and temples — the two areas where change becomes visible earliest in male pattern loss
• Energy, morning alertness and blood-pressure symptoms on standing — the practical symptoms that would accompany meaningful cortisol-axis suppression
• Confidence and appearance-related mood — the outcome that motivated treatment in the first place, and the one the trials measured directly through patient-reported scoring

Success at 6 months is best defined in advance as any one of: a measurable increase in target-area hair count over baseline, a reduction in daily shedding sustained over at least a month, or a visible improvement on side-by-side standardized photographs. Absence of all three at 6 months, with adherence confirmed and deficiency states corrected, is a reasonable definition of non-response.

Emerging Research

The near-term picture is dominated by one question — whether the Phase 3 dataset survives regulatory and peer review intact — and by a second-order question of whether a topical androgen blocker turns out to be the best way to intercept this pathway at all.

• Regulatory submission and full publication of the pivotal dataset: NCT05910450 (SCALP1, Phase 3, 703 men, co-primary endpoints of change in non-vellus target-area hair count and patient-rated hair coverage at 6 months) and NCT05914805 (SCALP2, Phase 3, 762 men, identical design) both completed, in January 2026 and July 2025 respectively. Cosmo Pharmaceuticals has stated it will submit the full dataset for peer-reviewed publication and file a United States application in early 2027. This is the single most consequential pending event: absolute hair-count changes per square centimetre, the reason for the threefold discrepancy in relative effect between two identically designed trials, and the full adverse-event tables are all currently unavailable, and any of them could shift the assessment in either direction.

• The unpublished proof-of-concept comparison against minoxidil: NCT02279823 (Phase 2, 95 men, cortexolone 17α-propionate 5% solution versus minoxidil 5% versus vehicle, twice daily for 26 weeks, primary endpoints target-area hair count and self-assessed hair growth) completed in December 2015 and has never reported results. It remains the only head-to-head comparison against an established treatment ever conducted with this compound. Its release would answer the comparative-effectiveness question that the entire Phase 3 programme, being vehicle-controlled, was not designed to address.

• Competing mechanisms that could displace it: NCT06692465 (Phase 2, 180 Chinese men, GT20029 topical solution for male pattern hair loss) tests an androgen receptor degrader rather than an antagonist — a molecule that destroys the receptor instead of competing for it, which would in principle avoid the continuous-occupancy requirement that makes clascoterone twice-daily and unforgiving of missed doses. Agrawal et al., 2026 catalogue this alongside prolactin-receptor biologics, follicle stem-cell activators and repurposed metabolic drugs, several of which target pathways upstream or entirely independent of androgens.

• Wider tolerability data from other indications: NCT06286397 (Phase 2, 75 participants, recruiting, clascoterone 1% cream versus vehicle for pilonidal sinus disease over 12 weeks, with physician-rated severity and quality-of-life co-primary endpoints and tissue immunohistochemistry as a secondary endpoint) is an academic, non-sponsor-run trial at the University of Pennsylvania. Independent trials of any size are scarce for this compound, and this one adds tissue-level inflammatory data that the sponsor programmes did not collect.

• Post-marketing surveillance that could weaken the safety case: Tao et al., 2026 analysed 1,085 adverse-event reports and flagged hypothalamic-pituitary-adrenal axis suppression, skin striae and abnormal hair growth as disproportionate signals. As prescription volumes rise with a hair indication and with far larger scalp doses, this database is the mechanism most likely to detect a systemic effect that the trials, with their selected populations and one-year horizon, were not powered to see.

• Formulation and combination questions still open: Draelos et al., 2025 established that clascoterone remains chemically stable when layered with a range of other topical agents, with 98% to 119% recovery. That removes chemical incompatibility as an objection to combination use but says nothing about whether clascoterone plus minoxidil, or clascoterone plus low-dose oral finasteride, produces additive clinical benefit — the combination question that matters most in practice and that no registered trial currently addresses.

Conclusion

Clascoterone is a hormone blocker applied to the skin that occupies the docking sites male-type hormones use inside hair follicles, then breaks down into an inactive form once it reaches the bloodstream. That design is the point: it aims at the hormonal driver of pattern hair loss without the whole-body effects that lead many people to decline or abandon the oral options.

The strongest published evidence comes from its approved use on facial skin, where it reduces oiliness and blemishes with very low whole-body hormone exposure. For the scalp, two large late-stage trials in men reported gains in visible hair and in how men rated their own coverage, gains that kept building over a year and faded once treatment stopped. The weakness is availability rather than trial size: those results were released only by Cosmo Pharmaceuticals, which owns the product, never published in full — while the clinics selling the competing options carry a revenue interest of their own.

The drawbacks reported so far are mostly local: redness, itching, scaling and dryness where the solution goes. Two whole-body signals sit behind them, a small rise in blood potassium and a warning that the body’s own stress-hormone output may be dampened, neither studied at the amount the scalp regimen delivers. Women, advanced thinning, and use beyond a year sit outside what has been tested. Clascoterone therefore sits in an unusual place: a well-characterized molecule with a good skin-tolerance record, attached to a hair-loss dataset that stays closed to independent review.

Top - Benefits - Risks - Protocol